WATERTOWN, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc. (Dicerna), a second generation RNA interference (RNAi) company developing novel therapeutics utilizing its proprietary Dicer Substrate Technology™ and Dicer Substrate siRNA (DsiRNA) molecules, today announced that Martin D. Williams, chief business officer, and scientific co-founders John Rossi, Ph.D., and Mark Behlke, M.D., Ph.D., will be presenting at the following conferences in September:
